The Chronic Liver Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Chronic Liver Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chronic Liver Disease. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chronic Liver Disease and features dormant and discontinued products.
GlobalData tracks 15 drugs in development for Chronic Liver Disease by 13 companies/universities/institutes. The top development phase for Chronic Liver Disease is preclinical with five drugs in that stage. The Chronic Liver Disease pipeline has 14 drugs in development by companies and one by universities/ institutes. Some of the companies in the Chronic Liver Disease pipeline products market are: HepaRegeniX, PrimeGen Global and Resolution Therapeutics.
The key targets in the Chronic Liver Disease pipeline products market include Dual Specificity Mitogen Activated Protein Kinase Kinase 4, Kappa Type Opioid Receptor, and High Mobility Group Protein B1.
The key mechanisms of action in the Chronic Liver Disease pipeline product include Dual Specificity Mitogen Activated Protein Kinase Kinase 4 Inhibitor with two drugs in Phase I. The Chronic Liver Disease pipeline products include four routes of administration with the top ROA being Oral and five key molecule types in the Chronic Liver Disease pipeline products market including Small Molecule, and Cell Therapy.
Chronic Liver Disease overview
Chronic liver disease is a progressive decline in liver functions, encompassing crucial roles such as clotting factor and protein production, detoxification, and bile excretion. It involves a continual cycle of inflammation, destruction, and regeneration of liver parenchyma, culminating in fibrosis and cirrhosis. Cirrhosis, the advanced stage, disrupts liver architecture, creating nodules, reorganizing vasculature, inducing neo-angiogenesis, and depositing extracellular matrix. The cellular mechanism involves stellate cell and fibroblast recruitment, leading to fibrosis, while hepatic stem cells play a pivotal role in parenchymal regeneration. Understanding this complex process is essential for effective management of chronic liver diseases.
For a complete picture of Chronic Liver Disease’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
